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Abstract
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Estrogens control many aspects of pituitary gland biology, including regulation of lactotroph
homeostasis and synthesis and secretion of prolactin. In rat models, these actions are strain
specific and heritable, and multiple quantitative trait loci (QTL) have been mapped that impact the
responsiveness of the lactotroph to estrogens. One such QTL, Ept7, was mapped to RNO7 in
female progeny generated in an intercross between BN rats, in which the lactotroph population is
insensitive to estrogens, and ACI rats, which develop lactotroph hyperplasia/adenoma and
associated hyperprolactinemia in response to estrogen treatment. The primary objective of this
study was to confirm the existence of Ept7 and to quantify the impact of this QTL on
responsiveness of the pituitary gland of female and male rats to 17β-estradiol (E2) and
diethylstilbestrol (DES), respectively. Secondary objectives were to determine if Ept7 influences
the responsiveness of the male reproductive tract to DES and to identify other discernible
phenotypes influenced by Ept7. To achieve these objectives, a congenic rat strain that harbors BN
alleles across the Ept7 interval on the genetic background of the ACI strain was generated and
characterized to define the effect of administered estrogens on the anterior pituitary gland and
male reproductive tissues. Data presented herein indicate Ept7 exerts a marked effect on
development of lactotroph hyperplasia in response to estrogen treatment, but does not affect
atrophy of the male reproductive tissues in response to hormone treatment. Ept7 was also observed
to exert gender specific effects on body weight in young adult rats.

Introduction

NIH-PA Author Manuscript

Estrogens act through their cognate receptors to regulate gene expression, cell proliferation
and/or cell survival in multiple tissues. One well studied estrogen responsive cell type is the
prolactin (PRL)-producing lactotroph of the anterior pituitary gland. Estrogens enhance
transcription of the PRL gene, stimulate lactotroph proliferation and prolong lactotroph
survival, and thereby regulate lactotroph homeostasis and the level of circulating PRL
(Sarkar et al. 1998; Sarkar 2006; Schlechte 2007; Spady et al. 1999a). Because of these
actions on the lactotroph, estrogens are suspected to contribute to development of
prolactinoma, which constitute the most common type of pituitary tumor in humans
(Schlechte 2007). In rat models, the actions of estrogens on the lactotroph are strain specific
and heritable (Shull et al. 2007; Spady et al. 1999c; Strecker et al. 2005; Wiklund et al.
1981a, b; Wiklund and Gorski 1982). Multiple quantitative trait loci (QTL) have been
mapped that impact the responsiveness of the pituitary lactotroph to estrogens (Kurz et al.
2008; Shull et al. 2007; Strecker et al. 2005; Wendell and Gorski 1997). One such QTL,
Ept7, was mapped to RNO7 in female progeny generated in an intercross between BN rats,
in which the lactotroph population is relatively insensitive to estrogens, and ACI rats, which
exhibit a dramatic increase in the size of the anterior pituitary gland resulting from
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development of lactotroph hyperplasia/adenoma in response to estrogen treatment (Shull et
al. 2007).

NIH-PA Author Manuscript

QTL that influence other estrogen regulated phenotypes have been mapped to the same
region of RNO7 as Ept7. Emca4, a QTL that influences susceptibility to estrogen-induced
mammary cancer was mapped to RNO7 in a BNxACI intercross (Schaffer et al. 2006).
Teswt1, a QTL that influences the weight of the testes in male rats treated with the synthetic
estrogen diethylstilbestrol (DES) was mapped to RNO7 using a panel of 30 recombinant
inbred strains generated by crossing Lewis and Fischer 344 rats (Tachibana et al. 2006). The
genetic variant(s) underlying these QTL and the mechanism(s) through which the variant(s)
impact(s) estrogen action in the pituitary gland, mammary gland and testis are not known.
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The primary objective of this study was to confirm the existence of Ept7 and to quantify the
impact of this QTL on responsiveness of the pituitary gland to estrogens. Secondary
objectives were to determine if Ept7 influences the responsiveness of the male reproductive
tract to estrogens and to identify other discernible phenotypes influenced by Ept7. To
achieve these objectives, we generated a congenic rat strain in which BN alleles across the
Ept7 interval were introgressed onto the genetic background of the ACI strain, and defined
the effect of administered estrogens on the anterior pituitary gland and male reproductive
tissues. Data presented herein indicate Ept7 exerts a marked effect on development of
lactotroph hyperplasia in response to estrogen treatment, but does not affect atrophy of the
male reproductive tissues in response to hormone treatment. Ept7 also exerts gender-specific
effects on body weight in young adult rats.

Material and methods
Care, treatment and phenotypic characterization of animals
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All procedures involving live animals were approved by our Institutional Animal Care and
Use Committee. ACI/SegHsd (ACI) and BN/SsNHsd (BN) rats were obtained from Harlan
Sprague Dawley, Inc. (Indianapolis, IN). The ACI.BN-Ept7 congenic rat strain was
generated in our laboratory as described below. All rats were housed in a barrier facility
under controlled temperature, humidity, and 12-h light/12-h dark conditions. This facility
was accredited by the American Association for Accreditation of Laboratory Animal Care
and operated in accordance with the Guide for the Care and Use of Laboratory Animals
(DHHS Pub. 85-23). All procedures related to the care and treatment of experimental
animals have been described (Gould et al. 2006; Kurz et al. 2008; Shull et al. 2007; Spady et
al. 1999c; Strecker et al. 2005). Silastic™ tubing implants containing the synthetic estrogen
DES were prepared as described previously and were surgically inserted into 9-week-old
male rats (Gould et al. 2006; Kurz et al. 2008; Shull et al. 2007; Spady et al. 1999c; Strecker
et al. 2005). Female rats were similarly treated using Silastic™ implants containing 17βestradiol (E2) (Shull et al. 1997; Gould et al. 2004; Schaffer et al. 2006; Schaffer et al.
2013). The control animals received empty implants. The rats were euthanized by
decapitation 12 weeks later and the anterior pituitary gland and reproductive tissues were
collected, photographed and evaluated as described previously (Gould et al. 2006; Kurz et
al. 2008; Shull et al. 2007; Spady et al. 1999c; Strecker et al. 2005). Representative
photographs are presented in Supplemental Fig. 1. Testes were fixed in Bouin’s, embedded
Mamm Genome. Author manuscript; available in PMC 2015 June 01.
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in paraffin, sectioned, stained with hematoxylin/eosin and evaluated by bright-field
microscopy (Bott et al. 2006; Cupp et al. 2003).
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Generation of the ACI.BN-Ept7 congenic rat strain
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The ACI.BN-Ept7 congenic rat strain (ILAR designated strain name is ACI.BN-(D7Rat164D7Uwm27)/Shul; Rat Genome Database strain identification number is 7248725) was
generated by mating an ACI male to a BN female to generate N1 progeny. N1 males were
backcrossed to ACI females to produce N2 progeny, and male progeny were mated to ACI
females to produce each subsequent generation of backcross progeny. At each generation of
back-crossing, the male progeny were genotyped to identify those that were heterozygous
for BN alleles across Ept7 on RNO7 (Tier 1 markers in Supplemental Table 1), the
heterozygous males were genotyped at markers on the remaining autosomes to identify
those rats that carried the fewest BN alleles at the background markers (Tier 2 markers in
Supplemental Table 1), and these males were utilized as breeders. An N5 male was
identified that was heterozygous across a large segment of RNO7 and homozygous for ACI
alleles at all background markers. Additional rounds of backcrossing heterozygous males to
ACI females resulted in a recombinant chromosome that harbored BN alleles from
D7Rat164 (69.5 Mb) to D7Uwm27 (100.11 Mb). A male rat carrying this chromosome was
mated to ACI females and heterozygous progeny were intercrossed to generate the ACI.BNEpt7 congenic strain. Animals from the ACI.BN-Ept7 strain were subsequently genotyped
using a panel of 123 microsatellite markers distributed across the genome to confirm the
genetic background of this congenic strain was that of the recipient ACI strain (Tier 3
markers in Supplemental Table 1). A schematic of the recombinant chromosome interval is
illustrated in Fig. 1.
Statistical analysis of data—Pituitary, body, and reproductive organ weights were
expressed as the mean ± standard error of the mean (SEM). Significance was determined by
one-way ANOVA using the statistical software R (R Development Core Team 2011).
Tukey’s HSD test was subsequently used to detect pairwise significant differences. p < 0.05
was considered significant.

Results
NIH-PA Author Manuscript

Ept7 influences induction of lactotroph hyperplasia by estrogen
Pituitary mass was utilized as a phenotypic indicator of responsiveness to estrogen. It is well
established that continuous treatment of female or male rats with naturally occurring or
synthetic estrogens induces lactotroph hyperplasia and increases, in a rat strain specific
manner, pituitary mass. Because pituitary mass in estrogen treated rats is highly correlated
with pituitary DNA content, an indicator of total cell number, and the concentration of
circulating PRL, the hormone product of the lactotroph, pituitary mass serves as a surrogate
indicator of absolute lactotroph number (Kurz et al. 2008; Spady et al. 1999a; Tachibana et
al. 2006). Treatment of female ACI rats with E2 for 12 weeks increased pituitary mass 5.8
fold, from 9.1 ± 0.4 mg in sham treated control rats to 53.1 ± 23.7 mg in treated rats (Fig. 2).
By contrast, E2 treatment increased pituitary mass only 1.7-fold in female BN rats and 4.1fold in female ACI.BN-Ept7 rats. Pituitary mass in treated ACI.BN-Ept7 rats was
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significantly less than observed in treated ACI rats, but greater than observed in treated BN
rats. The differences in the impact of E2 treatment on pituitary mass in the three rat strains
remained apparent when the data were corrected for body weight (data not shown, discussed
further below). These data indicate that BN alleles at Ept7 attenuate induction of lactotroph
hyperplasia in female rats treated for 12 weeks with the naturally occurring estrogen E2.
Induction of lactotroph proliferation was also significantly attenuated in female ACI.BNEpt7 rats treated with E2 for 28 weeks, when compared to treated ACI rats (data not shown).
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Parallel studies were performed using male rats treated with DES to determine if the impact
of Ept7 on induction of lactotroph hyperplasia was specific to gender or the chemical form
of estrogen used to induce lactotroph proliferation. The method used in this study to treat
male rats with DES was identical to that used in multiple published studies on genetic
control of estrogen action in the pituitary gland and was chosen to allow data generated in
this study to be compared to data generated in the previous studies (Spady et al. 1999c;
Strecker et al. 2005; Gould et al. 2006). Treatment of male ACI rats with DES for 12 weeks
increased pituitary mass 9.4-fold, from 8.7 ± 0.3 mg in sham treated controls to 81.3 ± 14.7
mg in treated rats (Fig. 3). By contrast, treatment with DES increased pituitary mass only
1.6-fold in BN rats. Pituitary mass was increased 6.1-fold in ACI.BN-Ept7 congenic rats in
response to DES treatment, from 7.8 ± 0.5 mg in control rats to 47.9 ± 5.9 mg in treated rats.
Pituitary mass in ACI.BN-Ept7 rats was significantly less than in treated ACI rats, but was
greater than observed in DES treated BN rats. The differences in the impact of DES
treatment on pituitary mass in the three rat strains remained apparent when the data were
corrected for body weight (data not shown). Photographs of representative tissues from each
experimental group of male rats are illustrated in Supplemental Fig. 1. These data further
support the conclusion that BN alleles at Ept7 significantly attenuate the ability of
administered estrogens to increase pituitary mass, and indicate that this action of Ept7 is not
specific to gender or to the chemical form of estrogen used to induce lactotroph
proliferation.
Ept7 does not affect DES-induced atrophy of male reproductive tissues
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Treatment of male rats with estrogens is known to decrease production of the gonadotropins
follicle stimulating hormone (FSH) and luteinizing hormone (LH), which in turn reduces
production of androgens by the testes, resulting in atrophy of the androgen dependent
reproductive tissues (Shin et al. 2009). In accord with this observation, micro-array data
from our laboratory indicate the mRNAs encoding the beta subunits of both FSH and LH
were dramatically reduced in response to DES treatment in both male ACI and male BN rats
(manuscript in preparation; Tong et al. 2012). Total testes weight was reduced by 88–91% in
response to 12 weeks of DES treatment in ACI, BN and ACI.BN-Ept7 rats and the degree to
which DES treatment induced atrophy of the testes did not differ between the 3 rat strains
(Fig. 4). Moreover, no significant differences in the degree to which testes weight was lost
in response to DES were observed upon comparison of the 3 strains when total testes weight
was normalized to body weight (data not shown). As expected, the effects of DES on
atrophy of the right and left testes were equivalent in each of the 3 rat strains (data not
shown). Interestingly, the weight of the testes in sham treated control BN rats was
significantly greater than in treatment matched ACI and ACI.BN-Ept7 rats, and this
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difference remained apparent upon normalization to body weight. Histological evaluation of
the testes revealed that treatment with DES resulted in a marked reduction in the size of the
seminiferous tubules, in apparent proportion to the reduction in size of the testis, and
depletion of developing germ cells (Fig. 5). No discernible differences in these responses to
DES were observed upon comparison between the 3 rat strains. Together, these data indicate
that Ept7 does not influence testes weight in control or DES treated rats or the degree to
which treatment with DES induces testicular atrophy and germ cell depletion.
Treatment with DES also induced atrophy of the epididymides and seminal vesicles. The
total weight of the epididymides was 85–90% lower in DES treated rats, compared to sham
treated control rats, and no significant differences were observed upon comparison of the
degree to which DES treatment reduced the weight of the epididymides in the 3 rat strains
(Fig. 6). Similarly, the total weight of the seminal vesicles was reduced by 81 to 93% in
response to DES treatment in each of the 3 rat strains (Fig. 7). No significant differences in
these phenotypes were observed when organ weights were normalized to body weight (data
not shown). Together, these data further indicate that Ept7 does not influence induction of
atrophy in male genital tissues by DES.

NIH-PA Author Manuscript

Ept7 harbors one or more genetic determinants of body weight
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Interval mapping analyses of a previously described population of 251 female (BNxACI)F2
rats using body weight at 9 weeks of age as the phenotype provided suggestive evidence of a
QTL on RNO7; the peak LOD score for this putative QTL was near D7Rat19 and ACI
alleles at this marker were associated with higher body weight in the (BNxACI)F2
population (Schaffer et al. 2006; data not shown). To determine whether a body weight QTL
resides within the Ept7 congenic interval, body weight was evaluated at 9 weeks of age, the
time point at which treatment with estrogen was initiated, and 21 weeks of age, the time
point at which the experiments were terminated. Female ACI rats weighed 2–4% more than
BN and ACI.BN-Ept7 rats at both 9 weeks of age (Fig. 8a) and 21 weeks of age (Fig. 8b);
however, these differences did not achieve statistical significance. The impact of E2
treatment on body weight in ACI and ACI.BN-Ept7 rats was negligible. By contrast, E2
treatment significantly inhibited growth of BN rats, resulting in an 11% difference in body
weight between sham treated control and E2 treated BN rats by 21 weeks of age (Fig. 8b).
Taken together, these data provide little additional support for the existence of a QTL within
the Ept7 congenic interval that influences body weight in female rats. Body weight was
similarly evaluated in male rats. At 9 weeks of age, BN and ACI.BN-Ept7 rats weighed
significantly more than ACI rats (Fig. 9a). Moreover, sham treated control and DES treated
ACI-BN-Ept7 rats weighed more, on average, than similarly treated ACI rats, although the
difference between the sham treated control groups did not attain statistical significance (p =
0.057) (Fig. 9b). Treatment with DES attenuated the increase in body weight normally
observed between 9 and 21 weeks of age and further resulted in a decrease in body weight
relative to that observed at 9 weeks of age. The amount of weight lost was equivalent in
ACI, BN and ACI.BN-Ept7 rats. These data suggest that the Ept7 congenic interval may
harbor a QTL at which the BN allele increases body weight in male rats.
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Ept7 genes and genetic variants
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The known BN segment within the Ept7 congenic interval extends over 30.6 Mb from
D7Rat164 (69.5 Mb) to D7Uwm27 (100.1 Mb). The maximum Ept7 interval extends over
32.1 Mb from D7Wox3 (68.2 Mb) to D7Rat17 (100.3 Mb). Using Ensembl BioMart and rat
genome assembly version 3.4, it was determined that the maximal Ept7 interval contains 146
known protein coding genes and 43 genes that encode various RNA types other than mRNA
(Supplemental Table 2). The genome ontology terms associated with these genes are
provided in Supplemental Table 3. Several Ept7 resident genes are annotated in relation to
regulation of cell proliferation and/or apoptosis, for examples Myc, Stk3 and Klf10, and two
are annotated in relation to response to estrogen stimulus, Tnfrsf11b and Angpt1. Using the
Variant Visualizer tool on Rat Genome Database, it was established that the maximal Ept7
congenic interval may harbor up to 55,115 variants between various genome sequence data
sets for ACI and BN/NHsd strains, approximately 1.8 variants per 1,000 nucleotides
(Supplemental Table 4). Non-synonymous nucleotide variants may exist in three of the
protein coding genes residing within the Ept7 congenic interval, RGD1562404, Eif3e and
Pkhd1l1 (Supplemental Table 5).
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Discussion

NIH-PA Author Manuscript

Data presented herein indicate that BN alleles at Ept7 on RNO7 attenuate the ability of the
naturally occurring estrogen E2 and the synthetic estrogen DES to induce gross enlargement
of the anterior pituitary gland in female and male rats, respectively. It is well established that
pituitary enlargement in ACI rats treated with estrogens results from induction of lactotroph
hyperplasia/adenoma, which leads to a dramatic increase in total lactotroph number and
hyperprolactinemia (Harvell et al. 2002; Kurz et al. 2008; Shull et al. 1997; Shull et al.
2007; Spady et al. 1999a; Spady et al. 1999b; Spady et al. 1999c; Strecker et al. 2005; Tong
et al. 2013). Therefore, we conclude that Ept7 harbors a genetic variant or variants that
influences, directly or indirectly, the responsiveness of the pituitary lactotroph to estrogens.
Ept7 was originally mapped as a genetic determinant of estrogen responsiveness in the
pituitary gland of female rats treated with E2. The data presented herein clearly indicate the
actions of Ept7 are not specific to gender or the chemical form of the administered hormone.
The site and mechanisms of action of Ept7 are not presently known. One possible site of
action is the pituitary lactotroph itself, which is capable of proliferating in vitro in response
to estrogens (Gersten and Baker 1970; Spady et al. 1999a). A second possible site of Ept7
action is the tuberoinfundibular dopaminergic neurons, which originate in the arcuate
nucleus and terminate in the median eminence in association with the hypophyseal portal
capillary network, which in turn transports released dopamine to the anterior pituitary gland
where it acts to inhibit lactotroph proliferation, PRL gene transcription, and PRL secretion
(Shaw-Bruha et al. 1996).
By contrast to its effects on induction of pituitary growth by estrogens, Ept7 did not exert a
discernible effect on the ability of DES to induce atrophy of male reproductive tissues
including testes, epididymides and seminal vesicles. These data indicate that the actions of
this locus on responsiveness to DES are cell type or tissue specific. Interestingly, Teswt1,
which was mapped by Tachibana and colleagues as a genetic determinant of testes weight in
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DES treated LEXF and FXLE recombinant inbred rats, did not affect induction of pituitary
growth in the same experimental animals (Tachibana et al. 2006). Together, the data from
these two studies strongly suggest that distinct genetic variants residing in the same region
of RNO7 affect induction of pituitary growth and atrophy of the male reproductive tissues
and further suggest the ACI and BN strains do not differ for the Teswt1 causal variants and
F344 and Lewis strains do not differ for the Ept7 causal variants.
The Ept7 congenic interval was observed in this study to harbor a variant or variants that
may exert a slight impact on body weight in female rats while exerting an opposing
significant impact on body weight in male rats. The site(s) and mechanism(s) of action of
this variant(s) are not presently known. Also not known is whether the same variant
influences induction of pituitary growth by DES and body weight. The Rat Genome
Database lists 4 reports of body weight QTL in this region of RNO7 (Laulederkind et al.
2013; Nigam et al. 2013). Interestingly, BN derived rats were utilized in each of the studies
in which all 4 of these body weight QTL were identified, suggesting the BN strain may
harbor a genetic variant on RNO7 that increases body weight in progeny that inherit this
variant.

NIH-PA Author Manuscript
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The peak LOD region of Ept7 and the distal segment of the Ept7 congenic interval are
orthologous to the 8q24 locus in humans (Shull et al. 2007). As noted above, Emca4, a QTL
that influences susceptibility to estrogen-induced mammary cancer in a BNxACI intercross,
has been mapped to the same region of RNO7 as Ept7 (Schaffer et al. 2006). Many common
diseases, including breast cancer, have been linked in genome wide association studies to
single nucleotide polymorphisms (SNPs) residing within the 8q24 locus (Easton et al. 2007;
Garcia-Closas and Chanock 2008). This 8q24 risk locus consists of a gene desert flanking
the proto-oncogene Myc. It is frequently hypothesized that genetic variants residing in the
8q24 risk locus influence disease susceptibility by impacting the binding of trans-acting
transcription factors to their cognate cis-acting elements, thereby exerting allele specific and
cell type specific effects on expression of Myc and consequently modulating the downstream
actions of Myc on regulation of cell proliferation and survival. Myc has been demonstrated
to be co-expressed with Pit1 in lactotrophs (Mukdsi et al. 2004). Treatment with DES
induces expression of Myc mRNA both in male ACI and male BN rats (manuscript in
preparation; Tong et al. 2013). Ongoing studies are focused on fine mapping the locations of
Ept7 and Emca4 loci on RNO7 so as to define the physical and functional relationships
between these loci and better understand the mechanisms through which these QTL
influence estrogen action in the anterior pituitary and mammary glands.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Ept7 congenic interval. RNO7, which is approximately 143 Mb in length, is depicted at the
top of the figure. Relative cytogenetic bands are indicated as black or white segments. The
Ept7 QTL was identified by interval mapping analyses of (BNxACI)F2 progeny. The Teswt1
QTL, which influences testes weight in male rats treated with DES, was mapped using
LEXF and FXLE recombinant inbred rat strains. The congenic interval for Ept7 is
illustrated, with the black region indicating homozygosity for BN alleles and the flanking
white regions representing the intervals of unknown genotype in which recombination
occurred. The remainder of RNO7 is homozygous for ACI alleles. The known BN congenic
interval for Ept7 lies between the markers D7Rat164 and D7Uwm27, and the maximum
Ept7 congenic interval extends from D7Wox3 to D7Rat17
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Fig. 2.
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Ept7 affects induction of pituitary growth in female rats by 17β-Estradiol. E2 was
administered through continuous release from Silastic™ implants that were inserted
subcutaneously when the rats were 9 weeks of age. Sham treated control rats received empty
implants. The rats were euthanized 12 weeks later. Pituitary weight was evaluated as an
indicator of E2-induced lactotroph hyperplasia. Each data bar represents the mean ±
standard error of the mean, n = 2–26 animals per group. 1, p ≤ 0.05 for comparison between
sham treated and 17β-Estradiol treated rats of same strain. 2, p ≤ 0.05 for comparison to ACI
rats that received the same treatment. 3, p ≤ 0.05 for comparison to BN rats that received the
same treatment
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Fig. 3.
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Ept7 affects induction of pituitary growth in male rats by diethylstilbestrol. DES was
administered through continuous release from Silastic™ implants that were inserted
subcutaneously when the rats were 9 weeks of age. Sham treated control rats received empty
implants. The rats were euthanized 12 weeks later. Pituitary weight was evaluated as an
indicator of the effects of DES on pituitary growth resulting from lactotroph hyperplasia.
Each data bar represents the mean ± standard error of the mean, n = 4–6 rats per group. 1, p
≤ 0.05 for comparison between sham treated and DES treated rats of same strain. 2, p ≤ 0.05
for comparison to ACI rats that received the same treatment. 3, p ≤ 0.05 for comparison to
BN rats that received the same treatment
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Fig. 4.

Ept7 does not affect atrophy of testes in response to DES. Rats were treated as described in
Fig. 3. The combined weight of the right and left testes was evaluated as an indicator of DES
induced atrophy. Each data bar represents the mean ± standard error of the mean, n = 5–6
rats per group. 1, p ≤ 0.05 for comparison between sham treated and DES treated rats of
same strain. 2, p ≤ 0.05 for comparison to ACI rats that received the same treatment. 3, p ≤
0.05 for comparison to BN rats that received the same treatment
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Fig. 5.

DES treatment results in depletion of developing germ cells. Rats were treated as described
in Fig. 3. Testes from representative sham treated control and DES treated ACI, BN and
ACI.BN-Ept7 rats are illustrated. Higher magnification images for testes from DES treated
rats are inset to illustrate depletion of germ cells

Mamm Genome. Author manuscript; available in PMC 2015 June 01.

Kurz et al.

Page 16

NIH-PA Author Manuscript
NIH-PA Author Manuscript

Fig. 6.

Ept7 does not affect atrophy of epididymides in response to DES. Rats were treated as
described in Fig. 3. The combined weight of the right and left epididymides was evaluated
as an indicator of DES induced atrophy. Each data bar represents the mean ± standard error
of the mean, n = 4–6 rats per group. 1, p ≤ 0.05 for comparison between sham treated and
DES treated rats of same strain. 2, p ≤ 0.05 for comparison to ACI rats that received the
same treatment. 3, p ≤ 0.05 for comparison to BN rats that received the same treatment
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Fig. 7.
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Ept7 does not affect atrophy of seminal vesicles in response to DES. Rats were treated as
described in Fig. 3. The combined weight of the right and left seminal vesicles was
evaluated as an indicator of DES induced atrophy. Each data bar represents the mean ±
standard error of the mean, n = 5–6 rats per group. 1, p ≤ 0.05 for comparison between sham
treated and DES treated rats of same strain. 2, p ≤ 0.05 for comparison to ACI rats that
received the same treatment. 3, p ≤ 0.05 for comparison to BN rats that received the same
treatment
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Fig. 8.
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Effect of Ept7 on body weight in female rats. Rats were treated as described in Fig. 2. Body
weight was evaluated at 9 weeks of age, the time treatment was initiated (a), and 21 weeks
of age, the time the animals were euthanized (b). Each data bar represents the mean ±
standard error of the mean; n = 6–35 rats per group in a, 2–26 rats per group in b. 1, p ≤ 0.05
for comparison between sham treated and DES treated rats of same strain. 2, p ≤ 0.05 for
comparison to ACI rats that received the same treatment. 3, p ≤ 0.05 for comparison to BN
rats that received the same treatment
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Fig. 9.
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Effect of Ept7 on body weight in male rats. Rats were treated as described in Fig. 3. Body
weight was evaluated at 9 weeks of age, the time treatment was initiated (a), and 21 weeks
of age, the time the animals were euthanized (b). Each data bar represents the mean ±
standard error of the mean; n = 9–10 rats per group in a, 5–6 rats per group in b. 1, p ≤ 0.05
for comparison between sham treated and DES treated rats of same strain. 2, p ≤ 0.05 for
comparison to ACI rats that received the same treatment. 3, p ≤ 0.05 for comparison to BN
rats that received the same treatment
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